GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Price-to-Free-Cash-Flow

AEterna Zentaris (TSX:AEZS) Price-to-Free-Cash-Flow : N/A (As of Apr. 26, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Price-to-Free-Cash-Flow?

As of today (2024-04-26), AEterna Zentaris's share price is C$2.65. AEterna Zentaris's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-4.75. Hence, AEterna Zentaris's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for AEterna Zentaris's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, AEterna Zentaris's highest Price-to-Free-Cash-Flow Ratio was 17.61. The lowest was 4.65. And the median was 10.15.

TSX:AEZS's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

AEterna Zentaris's Free Cash Flow per Share for the three months ended in Dec. 2023 was C$-1.49. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was C$-4.75.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -13.70% per year.

During the past 13 years, AEterna Zentaris's highest 3-Year average Free Cash Flow per Share Growth Rate was 68.00% per year. The lowest was -81.90% per year. And the median was 31.20% per year.


AEterna Zentaris Price-to-Free-Cash-Flow Historical Data

The historical data trend for AEterna Zentaris's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Price-to-Free-Cash-Flow Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEterna Zentaris's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, AEterna Zentaris's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Price-to-Free-Cash-Flow falls into.



AEterna Zentaris Price-to-Free-Cash-Flow Calculation

AEterna Zentaris's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.65/-4.752
=N/A

AEterna Zentaris's Share Price of today is C$2.65.
AEterna Zentaris's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.75.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

AEterna Zentaris  (TSX:AEZS) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


AEterna Zentaris Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (TSX:AEZS) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.